Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2012

Open Access 01-12-2012 | Commentary

Cost-effectiveness analysis for clinicians

Author: Suzanne R Hill

Published in: BMC Medicine | Issue 1/2012

Login to get access

Abstract

In a climate of economic uncertainty, cost effectiveness analysis is a potentially important tool for making choices about health care interventions. Methods for such analyses are well established, but the results need to be interpreted carefully and are subject to bias. Making decisions based on results of cost-effectiveness analyses can involve setting thresholds, but for individual patients, there needs to be disaggregation of benefits and harms included in a quality adjusted life year to ensure appropriate consideration of benefits and harms as well as personal preferences and circumstances.
Literature
1.
Detsky AS, Naglie IG: A clinician's guide to cost-effectiveness analysis. Ann Intern Med. 1990, 113: 147-154.CrossRefPubMed
2.
Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, Lightwood J, Williams L, Goldman L: Comparing impact and cost-effectiveness of primary prevention: strategies for lipid-lowering. Ann Intern Med. 2009, 150: 243-254.CrossRefPubMed
3.
Yong JHE, Schuh S, Rashidi R, Vanderby S, Lau R, Laporte A, Nauenberg E, Ungar WJ: A cost effectiveness analysis of omitting radiography in diagnosis of acute bronchiolitis. Pediatr Pulmonol. 2009, 44: 122-127. 10.1002/ppul.20948.CrossRefPubMed
4.
North RB, Kidd D, Shipley J, Taylor RS: Spinal cord stimulation versus reoperation for failed back surgery syndrome: a cost effectiveness and cost utility analysis based on a randomized, controlled trial. Neurosurgery. 2007, 61: 361-369. 10.1227/01.NEU.0000255522.42579.EA.CrossRefPubMed
5.
Eckman MH, Rosand J, Greenberg SM, Gage BF: Cost-Effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med. 2009, 150: 73-83.CrossRefPubMed
6.
Udvarhelyi IS, Colditz GA, Rai A, Epstein AM: Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly?. Ann Intern Med. 1992, 116: 238-244.CrossRefPubMed
7.
Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL: Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA. 1999, 282: 1453-1457. 10.1001/jama.282.15.1453.CrossRefPubMed
8.
Hill SR, Mitchell AS, Henry DA: Problems in the conduct of pharmacoeconomic evaluations. JAMA. 2000, 283: 2116-2121. 10.1001/jama.283.16.2116.CrossRefPubMed
9.
Baker CB, Johnsrud MT, Crismon ML, Rosenheck RA, Woods SW: Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry. 2003, 183: 498-506. 10.1192/bjp.183.6.498.CrossRefPubMed
10.
Garattini L, Koleva D, Casadei G: Modeling in pharmacoeconomic studies: funding sources and outcomes. Int J Technol Assess Health Care. 2010, 26: 330-333. 10.1017/S0266462310000322.CrossRefPubMed
11.
Hartmann M, Knoth H, Schulz D, Knoth S: Industry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisations. Br J Cancer. 2003, 89: 1405-1408. 10.1038/sj.bjc.6601308.CrossRefPubMedPubMedCentral
12.
Garattini L, De Compadri P, Clemente R, Cornago D: Economic evaluations in Italy: a review of the literature. Int J Technol Assess Health Care. 2003, 19: 685-691.CrossRefPubMed
13.
Jang S, Chae YK, Haddad T, Majhail NS: Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review. Breast Cancer Res Treat. 2010, 121: 273-279. 10.1007/s10549-010-0870-7.CrossRefPubMed
14.
Polyzos NP, Valachis A, Mauri D, Ioannidis JP: Industry involvement and baseline assumptions of cost-effectiveness analyses: diagnostic accuracy of the Papanicolaou test. CMAJ. 2011, 183: E337-343. 10.1503/cmaj.101506.CrossRefPubMedPubMedCentral
15.
Peura PK, Martikainen JA, Purmonen TT, Turunen JH: Sponsorship-related outcome selection bias in published economic studies of triptans: systematic review. Med Decis Making. 2011.
16.
Clemens K, Townsend R, Luscombe F, Mauskopf J, Osterhaus J, Bobula J: Methodological and conduct principles for pharmacoeconomic research Pharmaceutical Research and Manufacturers of America. Pharmacoeconomics. 1995, 8: 169-174. 10.2165/00019053-199508020-00008.CrossRefPubMed
17.
Drummond M, Brown R, Fendrick AM, Fullerton P, Neumann P, Taylor R, Barbieri M, ISPOR Task Force: Use of pharmacoeconomics information--report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health. 2003, 6: 407-416. 10.1046/j.1524-4733.2003.64245.x.CrossRefPubMed
18.
Drummond MF, Schwartz JS, Jönsson B, Luce BR, Neumann PJ, Siebert U, Sullivan SD: Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care. 2008, 24: 244-258. discussion 362-368CrossRefPubMed
19.
Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for economic development. 2001, Geneva: WHO
20.
Pearson SD, Rawlins MD: Quality, innovation, and value for money: NICE and the British National Health Service. JAMA. 2005, 294: 2618-2622. 10.1001/jama.294.20.2618.CrossRefPubMed
21.
Appleby J, Devlin N, Parkin D, Buxton M, Chalkidou K: Searching for cost effectiveness thresholds in the NHS. Health Policy. 2009, 91: 239-245. 10.1016/j.healthpol.2008.12.010.CrossRefPubMed
22.
Simoens S, Dooms M: How much is the life of a cancer patient worth? A pharmaco-economic perspective. J Clin Pharm Ther. 2011, 36: 249-256. 10.1111/j.1365-2710.2010.01181.x.CrossRefPubMed
23.
Metadata
Title
Cost-effectiveness analysis for clinicians
Author
Suzanne R Hill
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2012
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/1741-7015-10-10

Other articles of this Issue 1/2012

BMC Medicine 1/2012 Go to the issue

Research article

Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy

Research article

Intracranial hemorrhage in adult patients with hematological malignancies

Opinion

Towards a genuinely medical model for psychiatric nosology

Review

New treatments for influenza

Research article

Effects of phlebotomy-induced reduction of body iron stores on metabolic syndrome: results from a randomized clinical trial

Commentary

Location, location, location: the BRMS1 protein and melanoma progression